Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Samuel Z. Stentz"'
Autor:
Changpeng Lu, Joseph H. Lubin, Vidur V. Sarma, Samuel Z. Stentz, Guanyang Wang, Sijian Wang, Sagar D. Khare
Specific molecular recognition of substrates by enzymes, e.g., proteases, is critical for maintaining the robustness of crucial life processes. The ability to predictably tailor protease specificity would enable targeted proteolytic cleavage of any c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bda5c32099fa12647d4cdfd881c3dc95
Autor:
Changpeng Lu, Joseph H. Lubin, Vidur V. Sarma, Samuel Z. Stentz, Guanyang Wang, Sijian Wang, Sagar D. Khare
Publikováno v:
bioRxiv
Site-specific proteolysis by the enzymatic cleavage of small linear sequence motifs is a key post-translational modification involved in physiology and disease. The ability to robustly and rapidly predict protease substrate specificity would also ena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::718540de64658369aa37a0439feef3af
https://doi.org/10.1101/2023.02.16.528728
https://doi.org/10.1101/2023.02.16.528728
Autor:
Quoc D. Mac, Anirudh Sivakumar, Hathaichanok Phuengkham, Congmin Xu, James R. Bowen, Fang-Yi Su, Samuel Z. Stentz, Hyoungjun Sim, Adrian M. Harris, Tonia T. Li, Peng Qiu, Gabriel A. Kwong
Publikováno v:
Nat Biomed Eng
Immune checkpoint blockade (ICB) therapy does not benefit the majority of treated patients, and those who respond to the therapy can become resistant to it. Here we report the design and performance of systemically administered protease activity sens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac1d27abf6230ff6f87aadaea1551a7b
https://europepmc.org/articles/PMC8957521/
https://europepmc.org/articles/PMC8957521/
Autor:
Anirudh Sivakumar, Gabriel A. Kwong, Quoc D. Mac, Fang-Yi Su, Hathaichanok Phuengkham, Samuel Z Stentz, Bowen, Peng Qiu, Adrian M Harris, Li Tt, Congmin Xu, Sim H
Immune checkpoint blockade (ICB) therapy has transformed cancer treatment, yet most patients do not derive clinical benefit and responders can acquire resistance to therapy. Noninvasive biomarkers are needed to indicate early on-treatment response an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5fdd4f523f40ad879519f12c30cf096a
https://doi.org/10.1101/2020.12.10.420265
https://doi.org/10.1101/2020.12.10.420265
Autor:
Adrian M Harris, Samuel Z Stentz, Gabriel A. Kwong, Anirudh Sivakumar, Quoc D. Mac, Hathaichanok Phuengkham, Tonia Li, Peng Qiu, James Bowen, Hyoung Sim, Fang-Yi Su, Congmin Xu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Despite the curative potential of immune checkpoint blockade (ICB) therapy, only small subsets of patients achieve tumor regression while many responders relapse and acquire resistance. Monitoring treatment response and detecting the onset
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::112d0b5023b91280cd60085261e019b5
https://doaj.org/article/fe831172323f470499bff3d2f5063dea
https://doaj.org/article/fe831172323f470499bff3d2f5063dea
